The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; none of the 32 sources its claims cite is checked for support yet.
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Open accessAbstract
Biochemical and immunocytochemical analyses were performed to evaluate the composition of the amyloid beta protein (A beta) deposited in the brains of patients with Alzheimer's disease (AD). To quantitate all A beta s present, cerebral cortex was homogenized in 70% formic acid, and the supernatant was analyzed by sandwich enzyme-linked immunoabsorbent assays specific for various forms of A beta. In 9 of 27 AD brains examined, there was minimal congophilic angiopathy and virtually all A beta (96%) ended at A beta 42(43). The other 18 AD brains contained increasing amounts of A beta ending at A beta 40. From this set, 6 brains with substantial congophilic angiopathy were separately analyzed. In these brains, the amount of A beta ending at A beta 42(43) was much the same as in brains with minimal congophilic angiopathy, but a large amount of A beta ending at A beta 40 (76% of total A beta) was also present. Immunocytochemical analysis with monoclonal antibodies selective for A beta s ending at A beta 42(43) or A beta 40 confirmed that, in brains with minimal congophilic angiopathy, virtually all A beta is A beta ending at A beta 42(43) and showed that this A beta is deposited in senile plaques of all types. In the remaining AD brains, A beta 42(43) was deposited in a similar fashion in plaques, but, in addition, widely varying amounts of A beta ending at A beta 40 were deposited, primarily in blood vessel walls, where some A beta ending at A beta 42(43) was also present. These observations indicate that A beta s ending at A beta 42(43), which are a minor component of the A beta in human cerebrospinal fluid and plasma, are critically important in AD where they deposit selectively in plaques of all kinds.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In Alzheimer’s disease (AD) brain, Aβ ending at Aβ42(43) is the predominant deposited species in cases with minimal congophilic angiopathy, while Aβ40 becomes prominent mainly in brains with substantial vascular amyloid. The authors conclude that Aβ42(43), though a minor secreted species, is critically important in AD because it deposits selectively in senile plaques of all types.
Key findings
- In 9 of 27 AD brains with minimal congophilic angiopathy, virtually all Aβ (96%) ended at Aβ42(43); BC-05/4G8 detected 4663 ± 421 pmol/g versus BAN-50/BC-05 at 714 ± 68 pmol/g, while BA-27/4G8 detected only 216 ± 38 pmol/g.
- In 6 AD brains with substantial congophilic angiopathy, Aβ42(43) amounts were similar to minimal-angiopathy brains (BC-05/4G8: 5089 ± 409 pmol/g; BAN-50/BC-05: 826 ± 119 pmol/g), but Aβ40 was dramatically increased (BA-27/4G8: 13,607 ± 3397 pmol/g; BAN-50/BA-27: 5001 ± 2164 pmol/g). The abstract reports 76% of total Aβ ended at Aβ40 in these brains; the Results state an average of 67%.
- Total Aβ in 27 AD brains ranged from at least 500 to 4400 times that in plaque-free control brain; 98.5% of total Aβ required formic acid for solubilization and only 1.5% was extracted into Tris-saline.
- Immunocytochemistry showed BC-05 and 4G8 intensely labeled all plaque types and vascular amyloid, whereas BA-27 stained vascular amyloid well but stained plaque cores less intensely and almost failed to stain uncored plaques.
Methods
- AD and plaque-free control cerebral cortex was homogenized directly in 70% formic acid or sequentially extracted first into Tris-saline buffer with protease inhibitors and then into 70% formic acid.
- Aβ was quantitated by sandwich ELISAs specific for forms ending at Aβ40 (BA-27/4G8 or BAN-50/BA-27) or Aβ42(43) (BC-05/4G8 or BAN-50/BC-05), with some samples fractionated by Superose 12 size exclusion chromatography.
- Samples included an initial 3 AD and 3 control brains, then 27 AD and 6 plaque-free control brains; immunocytochemistry used formalin- or methacarn-fixed inferior temporal cortex with BA-27, BC-05, and 4G8 antibodies.
Limitations
- The paper does not state a formal limitations section. The authors note that BAN-50 cannot capture Aβs beginning at or beyond Aβ17, so the increased Aβ detected with 4G8 may indicate considerable amino-terminally truncated Aβ, but they caution this interpretation because other factors such as isoaspartates at Aβ1 and Aβ37 may diminish BAN-50 capture.
- The authors address the concern that BA-27 epitope destruction during fixation could distort immunocytochemistry, arguing against it because brains with minimal vascular amyloid had virtually all Aβ ending at Aβ42(43).
- Evident from the text: subgroup analyses rely on small numbers (e.g., 9 minimal and 6 substantial congophilic angiopathy cases), and no formal statistical comparisons are reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
25 Own result · 10 No full text of the sources · 6 Own method · 4 Not checked yet · 4 Own interpretation · 2 Sources not found · 1 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and large amounts of A{3C40 were deposited in some brains (Fig. 2).”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Analysis of A{3 in 27 AD and 6
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the remaining brains had increasing amounts of A{3C40'”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Analysis of A{3 in 27 AD and 6
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Based on this upper limit, the total A{3 in the 27 AD brains ranged from at least SOO to 4400 times that in plaque-free control brain.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Analysis of A{3 in 27 AD and 6
plaincorrelationaln = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: The recovery of synthetic Aβ added to control brain applies to endogenous Aβ in AD brain.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In these brains, A{3C40' measured with BA-27/4G8 (13607 :+: 3397 pmol/g) and BAN-SOIBA-27 (SOOI :+: 2164 pmol/g) ELISAs, was dramatically increased.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Analysis of A{3 in 27 AD and 6
plaincorrelationaln = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: The recovery of synthetic Aβ added to control brain applies to endogenous Aβ in AD brain.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In many AD brains, virtually all A{3 was A{3C42(4:Jl'”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Analysis of A{3 in 27 AD and 6
plainn = 27- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and showed that this Ap is deposited in senile plaques of all types.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Abstract
plainn = 27- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the remaining AD brains, Ap42(43) was deposited in a similar fashion in plaques”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Abstract
plainn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but, in addition, widely varying amounts of Ap ending at Ap40 were deposited, primarily in blood vessel walls”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Abstract
plainn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but a large amount of Ap ending at Ap40 (76% of total Am was also present.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Abstract
plaincorrelationaln = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but the total A{3 present in control brain was invariably less than 7 pmol/g.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Analysis of A{3 in 27 AD and 6
plainn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 14
- Probably not a substantial claim. 2
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The BAN-50IBA-27 ELISA showed a total of 73 ± 28 pmol of A{3lg in AD brain, whereas the BAN-50/BC-05 ELISA detected 725 ± 347 pmol/g (Table I).”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > EXPERIMENTAL PROCEDURES
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the AD brains, 98.S% of the total A{3 present required formic acid for solubilization and only l.S9t}was extracted into Tris-saline.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Analysis of A{3 in 27 AD and 6
plainn = 27- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Both 4G8 and BC-OS intensely labeled the AD brain, whereas BA-27 showed very little labeling (Fig. 3).”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Sandwich ELISAs for A~Sandwich
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BA-27 stained vascular amyloid quite well but, in contrast to BC-OS and 4G8, stained the cores of classic neuritic plaques less intensely and almost completely failed to stain uncored (diffuse and uncored neuritic) plaques or the region surrounding plaque cores.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Sandwich ELISAs for A~Sandwich
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“4G8 and BC-OS labeled uncored (diffuse and uncored neuritic) plaques, the cores of classic neuritic plaques, the region surrounding plaque cores, and vascular amyloid.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Sandwich ELISAs for A~Sandwich
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In 9 of 27 AD brains examined, there was minimal congophilic angiopathy and virtually all Ap (96%) ended at AP42(43).”
- Also stated in: § Analysis of A{3 in 27 AD and 6 · plain
“Virtually all A{3 in the formic acid extracts from these 9 brains (96%) ended at A{342(43)”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Abstract
plaincorrelationaln = 9- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Analysis of A{3 in 27 AD and 6 · plain
In the paper
“The immunocytochemical results shown here and in a recent report by Iwatsubo et al. (21) demonstrate that BC-05 intensely stains all types of senile plaques, that vessels are stained by both BC-OS and BA-27, and that BA-27 stains plaques poorly, in many cases only faintly staining occasional cored plaques (Fig. 3).”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Sandwich ELISAs for A~Sandwich
What the sources say
- Not checked — no full text of the sourcecites [21] Iwatsubo, 1994, Neuron source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the 3 AD brains, the BA-27/4GB ELISA showed a total of93 ± 45 pmol of A,B/g whereas the BC-05/4G8 ELISA showed 3200 ± 1350 pmol of A,BIg (Table I).”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > EXPERIMENTAL PROCEDURES
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, it a ppears t hat deposition of A{3C42(43) in senile plaq ues is fundamental to AD path ogenesis with additi ona l deposition of A{3C40' prim aril y in blood vessel wa lls, occurring in some cases.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Analysis of A{3 in 27 AD and 6
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Th is finding is consistent with pr evious re ports (15,17,18) that most of the A{3 in AD brains is amino-ter mi na lly trunca te d or modifi ed.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > FIG.
What the sources say
plainn = 27- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The monoclonal antibodies employed were BAN-50 (anti-A{31-16), 4G8 (anti-Af3l7-24) (19), BA-27, which is specific for A{3 ending at A{340, and BC-05, which is specific for A{3 ending at A{342(43).”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Sandwich ELISAs for A~Sandwich
What the sources say
- Not checked — no full text of the sourcecites [9] Suzuki, 1994, Science source
- Not checked yetcites [19] Kim, 1988, Neurosci. Res. Commun.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In the brains of patients with Alzheimer's disease (AD),!amyloid composed of 4-kDa amyloid {3 protein (A{3) is deposited in senile plaques and in blood vessel walls.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Abstract
What the sources say
- Not checked — no full text of the sourcecites [1] Yamaguchi, 1988, Acta Neuropathol. source
- Not matchedcites [2] Masliah, 1990, Am. J. Pathol.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Recently, we and others have shown that normal processing of the large amyloid f3 protein precursor ({3-APP) secretes 4-kDa A(3 that is readily detected in human cerebrospinal fluid and in medium conditioned by cultured cells (3)(4)(5)(6).”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Abstract
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“As t his occurred, BC-05 in varia bly showed intense staini ng of all plaq ues as well as some staining of blood ves sel wa lls whereas BA-27 intensely staine d blood vess els a nd showed increa sing stai ning of A{3C40 in plaques, par ticul a rly ma t ure cored pla qu es, a lthough it never stained plaques to t he exte nt observed with BC-05.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Analysis of A{3 in 27 AD and 6
What the sources say
- Not matchedcites [22] Iwatsubo, 1995, Ann. Neurol.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Recent reports using this approach, particularly those of Roher and his colleagues, indicate that the SDS-insoluble amyloid in senile plaque cores is primarily A(31-42 (15,17)”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Abstract
What the sources say
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“In th ese br ai ns, A{3C42(43l staine d by BC-05 was deposited fir st in diffu se plaq ues , an d there was esse ntia lly no staining by BA-27.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Analysis of A{3 in 27 AD and 6
What the sources say
- Not matchedcites [22] Iwatsubo, 1995, Ann. Neurol.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Not matched
The paper relies on this without support.
The recovery of synthetic Aβ added to control brain applies to endogenous Aβ in AD brain.
“To assess Af3 recovery, synthetic Af3 (500 pmol of A{31-4o plus 500 pmol of Af31-42, Bachem) was added to samples of cerebral cortex (-0.5 g) from control brains prior to homogenization.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and both forms continued to increase substantially from 12 to 23 months, reaching levels like those seen in the AD brain (Gravina et al., 1995).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Gravina et al., 1995
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In our previous examination of insoluble A in 27 AD brains (Gravina et al., 1995), A42 predominated in 70% and, in 33%, there was essentially no A40 deposited.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Gravina et al., 1995
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the 30% in which A40 was the predominant species deposited, there was typically prominent congophilic angiopathy.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Gravina et al., 1995
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In most AD patients, very little A40 is deposited in the brain, but in ϳ33%, extraordinary amounts of A40 are deposited, and most of these patients show substantial amyloid angiopathy (Gravina et al., 1995).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Gravina et al., 1995
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“accumulates to a variable degree in the human AD brain”
From Aβ40 Inhibits Amyloid Deposition In Vivo (2007) · cites this paper as Gravina et al., 1995
The cited source says what the claim attributes to it.
In the citing paper
“In our previous study (Gravina et al., 1995), ELISAs for Ax-42 (BC-05/4G8) and Ax-40 (BA-27/4G8) showed that most of the A in AD brain is N-terminally truncated or modified.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Gravina et al., 1995
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, virtually all A terminated at A42 in the two AD brains examined (Fig. 5 K, L), as occurs in ϳ33% of AD cases (Gravina et al., 1995).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Gravina et al., 1995
In the citing paper
“In contrast, Aβ40, the major Aβ peptide secreted by cells, appears to be the predominant species deposited in the amyloid deposits in the cerebral vasculature (congophillic angiopathy, CAA) (Gravina et al., 1995; Iwatsubo et al., 1994).”
From Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice (2005) · cites this paper as Gravina et al., 1995
In the citing paper
“These data provide definitive in vivo confirmation of predictions inferred from (1) in vitro studies of Aβ aggregation, (2) effects of PS and certain APP mutations on Aβ production and deposition, and (3) analyses of Aβ peptides in the human AD brain (Gravina et al., 1995; Iwatsubo et al., 1994).”
From Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice (2005) · cites this paper as Gravina et al., 1995
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Abstract
“In these brains, the amount of Ap ending at AP42(43) was much the same as in brains with minimal congophilic angiopathy, but a large amount of Ap ending at Ap40 (76% of total Am was also present.”
§ Communication Amyloid 13 Protein (Af3) in Alzheimer's Disease Brain BIOCHEMICAL AND IMMUNOCYTOCHEMICAL ANALYSIS WITH ANTIBODIES SPECIFIC FOR FORMS ENDING AT A1340 OR AI342(43)* ( > Analysis of A{3 in 27 AD and 6
“On average, 67% of the A{3 in brains with substantial congophilic angiopathy ended at A{340”
Citations
Cites
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471
Self-citationProduction of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Self-citationAssembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.
Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J., Cotman, C., & Glabe, C. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48529-8 · Cited by 1,014
Roher, A. E., Lowenson, J. D., Clarke, S., Wolkow, C., Wang, R., Cotter, R. J., Reardon, I. M., Zürcher-Neely, H. A., Heinrikson, R. L., & Ball, M. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53661-9 · Cited by 799
Roher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, R. J., Gowing, E., & Ball, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10836 · Cited by 740
Research works printed but not linked: 4
- Masliah, 1990, Am. J. Pathol., 137, 1293
- Kim, 1988, Neurosci. Res. Commun., 2, 121
- Suzuki, 1994, Am. J. Pathol., 145, 452
- Iwatsubo, 1995, Ann. Neurol.
Cited by
Sorted by citations
Items 101–200 of 674
Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Yamada, K., & Nabeshima, T. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00081-4 · Cited by 192
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190
Amyloidogenesis of Natively Unfolded Proteins
Uversky, V. N. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533312 · Cited by 188
Mann, D. M. A., Iwatsubo, T., Ihara, Y., Cairns, N. J., Lantos, P. L., Bogdanović, N., Lannfelt, L., Winblad, B. G., Maat–Schieman, M. L. C., & Rossor, M. N. (1996) · Europe PMC (PubMed Central) · Cited by 184
Age and amyloid effects on human central nervous system amyloid‐beta kinetics
Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., Yarasheski, K., Sigurdson, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24454 · Cited by 200
High Levels of Circulating Aβ42 Are Sequestered by Plasma Proteins in Alzheimer's Disease
Kuo, Y., Emmerling, M. R., Lampert, H. C., Hempelman, S. R., Kokjohn, T. A., Woods, A. S., Cotter, R. J., & Roher, A. E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0552 · Cited by 183
Isoflurane induces hippocampal cell injury and cognitive impairments in adult rats
Lin, D., & Zuo, Z. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.011 · Cited by 181
Aβ42-Peptide Assembly on Lipid Bilayers
Yip, C. M., Darabie, A. A., & McLaurin, J. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00028-1 · Cited by 176
Stable Association of Presenilin Derivatives and Absence of Presenilin Interactions with APP
Thinakaran, G., Regard, J. B., Bouton, C. M. L. S., Harris, C. L., Price, D. L., Borchelt, D., & Sisodia, S. S. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0171 · Cited by 173
Alzheimer disease pathology as a host response
Castellani, R. J., Lee, H.-G., Zhu, X., Perry, G., & Smith, M. A. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318177eaf4 · Cited by 171
Decreased β-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
Otto, M., Esselmann, H., Schulz‐Schaeffer, W., Neumann, M., Schröter, A., Ratzka, P., Cepek, L., Zerr, I., Steinacker, P., Windl, O., et al. (2000) · Neurology · doi:10.1212/wnl.54.5.1099 · Cited by 170
A High-Throughput Screen for Compounds That Inhibit Aggregation of the Alzheimer’s Peptide
Kim, W., Kim, Y., Min, J., Kim, D. J., Chang, Y., & Hecht, M. H. (2006) · ACS Chemical Biology · doi:10.1021/cb600135w · Cited by 169
Qian, S., Jiang, P., Guan, X.-M., Singh, G., Trumbauer, M. E., Yu, H. H., Chen, H. Y., der Ploeg, L. H. T. V., & Zheng, H. (1998) · Neuron · doi:10.1016/s0896-6273(00)80999-x · Cited by 172
The amyloid precursor protein of Alzheimer’s disease and the Aβ peptide
Storey, & Cappai, R. (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00164.x · Cited by 172
Methionine residue 35 is important in amyloid β-peptide-associated free radical oxidative stress
Varadarajan, S., Yatin, S. M., Kański, J., Jahanshahi, F., & Butterfield, D. A. (1999) · Brain Research Bulletin · doi:10.1016/s0361-9230(99)00093-3 · Cited by 170
Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
McGrowder, D. A., Miller, F. G., Vaz, K., Nwokocha, C. R., Wilson-Clarke, C. F., Anderson, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 169
A Molecular Switch in Amyloid Assembly: Met35and Amyloid β-Protein Oligomerization
Bitan, G., Tarus, B., Vollers, S. S., Lashuel, H. A., Condron, M. M., Straub, J. E., & Teplow, D. B. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0349296 · Cited by 158
Carlson, G. A., Borchelt, D. R., Dake, A., Turner, S., Danielson, V., Coffin, J. D., Eckman, C., Meiners, J., Nilsen, S. P., Younkin, S. G., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1951 · Cited by 158
Self-citationKlafki, H., Abramowski, D., Swoboda, R., Paganetti, P., & Staufenbiel, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28655 · Cited by 159
Murphy, M. P., Hickman, L., Eckman, C. B., Uljon, S., Wang, R., & Golde, T. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11914 · Cited by 156
Self-citationDifferences in β-strand Populations of Monomeric Aβ40 and Aβ42
Ball, K. A., Phillips, A. H., Wemmer, D. E., & Head-Gordon, T. L. (2013) · Biophysical Journal · doi:10.1016/j.bpj.2013.04.056 · Cited by 157
Loss of Neprilysin Function Promotes Amyloid Plaque Formation and Causes Cerebral Amyloid Angiopathy
Farris, W., Schütz, S. G., Cirrito, J. R., Shankar, G. M., Sun, X., George, A., Leissring, M. A., Walsh, D. M., Qiu, W. Q., Holtzman, D. M., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070105 · Cited by 159
Beach, T. G., Kuo, Y., Spiegel, K., Emmerling, M. R., Sue, L. I., Kokjohn, K., & Roher, A. E. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.4.308 · Cited by 157
Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum
Schneider, P., Hampel, H. J., & Büerger, K. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00104.x · Cited by 154
Nontoxic Amyloid β Peptide1-42 Suppresses Acetylcholine Synthesis
Hoshi, M. M., Takashima, A., Murayama, M., Yasutake, K., Yoshida, N., Ishiguro, K., Hoshino, T., & Imahori, K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2038 · Cited by 151
Long amyloid beta-protein secreted from wild-type human neuroblastoma IMR-32 cells.
Asami-Odaka, A., Ishibashi, Y., Kikuchi, T., Kitada, C., & Suzuki, N. (1995) · Biochemistry · doi:10.1021/bi00032a022 · Cited by 153
Self-citationAβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains
Welander, H., Frånberg, J., Graff, C., Sundström, E., Winblad, B. G., & Tjernberg, L. O. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06170.x · Cited by 150
Jonghe, C. D., Zehr, C., Yager, D., Prada, C.-M., Younkin, S. G., Hendriks, L., Broeckhoven, C. V., & Eckman, C. B. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0202 · Cited by 151
Self-citationAmyloid‐β induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease
Cumming, R. C., & Schubert, D. A. (2005) · The FASEB Journal · doi:10.1096/fj.05-4195fje · Cited by 148
Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease.
(1998) · Europe PMC (PubMed Central) · Cited by 145
Alzheimer’s Disease as Proteolytic Disorders: Anabolism and Catabolism of β-Amyloid
Saido, T. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00033-5 · Cited by 140
Lewis, H. D., Beher, D., Cookson, N., Oakley, A. E., Piggott, M. A., Morris, C. M., Jaros, E., Perry, R., Ince, P. G., Kenny, R. A., et al. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00696.x · Cited by 143
Diffuse Plaques Contain C-terminal Aβ42and not Aβ40: Evidence From Cats and Dogs
Cummings, B. J., Satou, T., Head, E., Milgram, N. W., Cole, G. M., Savage, M. J., Podlisny, M. B., Selkoe, D. J., Siman, R. G., Greenberg, B., et al. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00062-0 · Cited by 140
Skoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194
Phosphatidylinositol and inositol involvement in alzheimer amyloid-β fibril growth and arrest
McLaurin, J., Franklin, T., Chakrabartty, A., & Fraser, P. E. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1677 · Cited by 141
Attems, J., Lintner, F., & Jellinger, K. A. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0822-6 · Cited by 139
Protective effects of asiaticoside derivatives against beta-amyloid neurotoxicity
Mook‐Jung, I., Shin, J., Yun, S. H., Huh, K., Koh, J. Y., Park, H. K., Jew, S., & Jung, M. W. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19991101)58:3 · Cited by 140
Carro, E., Trejo, J. L., Spuch, C., Bohl, D., Heard, J. M., & Torres‐Alemán, I. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.039 · Cited by 139
Spies, P. E., Slats, D., Sjögren, M. J. C., Kremer, B. P. H., Verhey, F. R. J., Rikkert, M. G. M. O., & Verbeek, M. M. (2010) · Current Alzheimer Research · doi:10.2174/156720510791383796 · Cited by 140
Jaeger, L. B., Dohgu, S., Hwang, M. C., Farr, S. A., Murphy, M. P., Fleegal, M. A., Lynch, J. L., Robinson, S. M., Niehoff, M. L., Johnson, S. N., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1074 · Cited by 142
Cerebral Amyloid Angiopathy and Vessel Dysfunction
Greenberg, S. M. (2002) · Cerebrovascular Diseases · doi:10.1159/000049149 · Cited by 135
Aged chimpanzees exhibit pathologic hallmarks of Alzheimer's disease
Edler, M. K., Sherwood, C. C., Meindl, R. S., Hopkins, W. D., Ely, J. J., ERWIN, J. M., Mufson, E. J., Hof, P. R., & Raghanti, M. A. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.07.006 · Cited by 138
Peskind, E. R., Li, G., Shofer, J., Quinn, J. F., Kaye, J. A., Clark, C. M., Farlow, M. R., DeCarli, C., Raskind, M. A., Schellenberg, G. D., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.936 · Cited by 131
“The A peptide is generated by proteolytic processing of the amyloid precursor protein into a series of fragments 38 to 42 amino acids long; A 42 represents about 10% of synthesized A but is by far the earliest and predominant A species deposited in plaques in AD.(5) Decreased concentration of A 42 in CSF is a consiste…”
BackgroundInfluentialBenzofuran derivatives as Aβ-aggregate-specific imaging agents for Alzheimer’s disease
Ono, M., Kung, M., Hou, C., & Kung, H. F. (2002) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(02)00326-8 · Cited by 131
Pathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives
Fisher, R. A., Miners, J. S., & Love, S. (2022) · Brain Pathology · doi:10.1111/bpa.13061 · Cited by 133
Xia, N., Liu, L., Harrington, M. G., Wang, J., & Zhou, F. (2010) · Analytical Chemistry · doi:10.1021/ac102257m · Cited by 136
Wiltfang, J., Av, S., Schnierstein, B., Kelemen, G., Matthies, U., Klafki, H., Staufenbiel, M., Huether, G., Rüther, E., & Kornhuber, J. (1997) · Electrophoresis · doi:10.1002/elps.1150180332 · Cited by 130
Alzheimer’s Retinopathy: Seeing Disease in the Eyes
Mirzaei, N., Shi, H., Oviatt, M., Doustar, J., Rentsendorj, A., Fuchs, D.-T. S., Sheyn, J., Black, K. L., Koronyo, Y., & Koronyo‐Hamaoui, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00921 · Cited by 136
Toyama, H., Ye, D. G., Ichise, M., Liow, J., Cai, L., Jacobowitz, D. M., Musachio, J. L., Hong, J. S., Crescenzo, M., Tipre, D. N., et al. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1780-5 · Cited by 126
The role of amyloid oligomers in neurodegenerative pathologies
Wells, C., Brennan, S. E., Keon, M., & Ooi, L. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.03.113 · Cited by 131
Okochi, M., Tagami, S., Yanagida, K., Takami, M., Kodama, T. S., Mori, K., Nakayama, T., Ihara, Y., & Takeda, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.11.028 · Cited by 123
Sequence Determinants of Enhanced Amyloidogenicity of Alzheimer Aβ42 Peptide Relative to Aβ40
Kim, W., & Hecht, M. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505763200 · Cited by 123
Circulating Biomarkers of Cognitive Decline and Dementia
Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120
Rodent Aβ Modulates the Solubility and Distribution of Amyloid Deposits in Transgenic Mice
Jankowsky, J. L., Younkin, L. H., Gonzales, V., Fadale, D. J., Slunt, H. H., Lester, H. A., Younkin, S. G., & Borchelt, D. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611050200 · Cited by 122
Self-citationThe amyloid cascade and Alzheimer's disease therapeutics: theory versus observation
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 130
Buchhave, P., Zetterberg, H., Blennow, K., Minthon, L., Janciauskiene, S. M., & Hansson, O. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.10.012 · Cited by 120
Sayre, L. M., Zagorski, M. G., Surewicz, W. K., Krafft, G. A., & Perry, G. L. (1997) · Chemical Research in Toxicology · doi:10.1021/tx970009n · Cited by 119
Contributions of DNA Damage to Alzheimer’s Disease
Lin, X., Kapoor, A., Gu, Y., Chow, M. J., Peng, J., Zhao, K., & Tang, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051666 · Cited by 117
Bressler, S. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.10.1589 · Cited by 117
Tai, L. M., Holloway, K., Male, D. K., Loughlin, J., & Romero, I. A. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00717.x · Cited by 118
Cleavage Agents for Soluble Oligomers of Amyloid β Peptides
Suh, J., Yoo, S., Kim, M. G., Jeong, K., Ahn, J. Y., Kim, M., Chae, P. S., Lee, T. Y., Lee, J.-H., Lee, J., et al. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200702399 · Cited by 115
Burdick, D., Kosmoski, J., Knauer, M. F., & Glabe, C. G. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01262-0 · Cited by 102
Plasma β Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men
Sundelöf, J. E., Giedraitis, V., Irizarry, M. C., Sundström, J., Ingelsson, E., Rönnemaa, E., Ärnlöv, J., Gunnarsson, M. D., Hyman, B. T., Basun, H., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.57 · Cited by 113
Hong, S., Quintero-Monzon, O., Ostaszewski, B. L., Podlisny, D. R., Cavanaugh, W. T., Yang, T., Holtzman, D. M., Cirrito, J. R., & Selkoe, D. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3272-11.2011 · Cited by 111
Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer’s disease
Shinohara, M., Murray, M. E., Frank, R. D., Shinohara, M., DeTure, M., Yamazaki, Y., Tachibana, M., Atagi, Y., Davis, M. D., Liu, C.-C., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1580-y · Cited by 123
A critical analysis of the ‘amyloid cascade hypothesis’
A. Armstrong, R. (2014) · Folia Neuropathologica · doi:10.5114/fn.2014.45562 · Cited by 110
Pryor, N. E., Moss, M. A., & Hestekin, C. N. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13033038 · Cited by 113
Moir, R. D., Atwood, C., Romano, D., Laurans, M. H., Huang, X., Bush, A. I., Smith, J. D., & Tanzi, R. E. (1999) · Biochemistry · doi:10.1021/bi982437d · Cited by 112
Yu, M., Chen, X., Liu, J., Ma, Q., Zhuo, Z., Chen, H., Zhou, L., Yang, S., Zheng, L., Ning, C., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.009 · Cited by 114
Donner, L., Fälker, K., Gremer, L., Klinker, S., Pagani, G., Ljungberg, L. U., Lothmann, K., Rizzi, F., Schaller, M., Gohlke, H., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf6240 · Cited by 114
Increased plasma amyloid β protein 1–42 levels in Down syndrome
Mehta, P. D., Dalton, A. J., Mehta, S. P., Kim, K. S., Sersen, E. A., & Wisniewski, H. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00966-x · Cited by 108
Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
Huynh, R. A., & Mohan, C. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00102 · Cited by 112
Bussière, T., Friend, P. D., Sadeghi, N., Wicinski, B. A., Lin, G. I., Bouras, C., Giannakopoulos, P., Robakis, N. K. R. K., Morrison, J. H., Perl, D. P., et al. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00056-8 · Cited by 108
Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid β-peptide
Jao, S., Ma, K., Talafous, J., Orlando, R., & Zagorski, M. G. (1997) · Amyloid · doi:10.3109/13506129709003835 · Cited by 107
Effect of Zinc Binding on β-Amyloid Structure and Dynamics: Implications for Aβ Aggregation
Rezaei‐Ghaleh, N., Giller, K., Becker, S., & Zweckstetter, M. (2011) · Biophysical Journal · doi:10.1016/j.bpj.2011.06.062 · Cited by 112
Kövari, E., Herrmann, F. R., Hof, P. R., & Bouras, C. (2012) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12003 · Cited by 105
Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease
Gao, C. M., Yam, A. Y., Wang, X., Magdangal, E., Salisbury, C., Peretz, D., Zuckermann, R. N., Connolly, M. D., Hansson, O., Minthon, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015725 · Cited by 105
“While nearly all cases of AD report Ab42containing plaques in the brain, approximately two thirds of them also report Ab40 deposits [11], and significant levels of Ab40 have”
BackgroundRare Individual Amyloid-β Oligomers Act on Astrocytes to Initiate Neuronal Damage
Narayan, P. S., Holmström, K. M., Kim, D.-H., Whitcomb, D. J., Wilson, M. R., George‐Hyslop, P. S., Wood, N. W., Dobson, C. M., Cho, K., Abramov, A. Y., et al. (2014) · Biochemistry · doi:10.1021/bi401606f · Cited by 105
ABC Transporters and the Alzheimer’s Disease Enigma
Wolf, A. M., Bauer, B., & Hartz, A. M. S. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00054 · Cited by 109
Comparing the Aggregation Free Energy Landscapes of Amyloid Beta(1–42) and Amyloid Beta(1–40)
Zheng, W., Tsai, M., & Wolynes, P. G. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08089 · Cited by 102
van Horssen, J., Otte‐Höller, I., David, G., Maat–Schieman, M. L. C., van den Heuvel, L. P., Wesseling, P., de Waal, R. M., & Verbeek, M. M. (2001) · Acta Neuropathologica · doi:10.1007/s004010100414 · Cited by 103
Aβ40 Reduces P-Glycoprotein at the Blood–Brain Barrier through the Ubiquitin–Proteasome Pathway
Hartz, A. M. S., Zhong, Y., Wolf, A. M., LeVine, H., Miller, D. S., & Bauer, B. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0350-15.2016 · Cited by 100
Kong, Z.-H., Chen, X., Hua, H.-P., Liang, L., & Liu, L.-J. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0989-7 · Cited by 99
Zhao, J., Paganini, L., Mucke, L., Gordon, M., Refolo, L., Carman, M., Sinha, S., Oltersdorf, T., Lieberburg, I., & McConlogue, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31407 · Cited by 84
The α5β1 Integrin Mediates Elimination of Amyloid-β Peptide and Protects Against Apoptosis
Matter, M. L., Zhang, Z., Nordstedt, C., & Ruoslahti, E. I. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.4.1019 · Cited by 97
Seppälä, T. T., Herukka, S., Hänninen, T., Tervo, S., Hallikainen, M., Soininen, H. S., & Pirttilä, T. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.205757 · Cited by 98
Anti-Viral Properties of Amyloid-β Peptides
Bourgade, K., Dupuis, G., Frost, E. H., & Fülöp, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160517 · Cited by 97
Endogenous β-amyloid production in presenilin-deficient embryonic mouse fibroblasts
Armogida, M., Petit-Paitel, A., Vincent, B., Scarzello, S., da Costa, C. A., & Checler, F. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1030 · Cited by 96
Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques
Kumar‐Singh, S. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00380.x · Cited by 101
Amadoro, G., Corsetti, V., Atlante, A., Florenzano, F., Capsoni, S., Bussani, R., Mercanti, D., & Calissano, P. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.001 · Cited by 95
Retinal Vasculopathy in Alzheimer’s Disease
Shi, H., Koronyo, Y., Rentsendorj, A., Fuchs, D.-T. S., Sheyn, J., Black, K. L., Mirzaei, N., & Koronyo‐Hamaoui, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.731614 · Cited by 91
The length of Amyloid-β in Hereditary Cerebral Hemorrhage with Amyloidosis, Dutch Type
Castaño, E. M., Prelli, F., Soto, C. A., Beavis, R. C., Matsubara, E., Shoji, M., & Frangione, B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.32185 · Cited by 91
Moir, R. D., Tseitlin, K. A., Soscia, S. J., Hyman, B. T., Irizarry, M. C., & Tanzi, R. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414176200 · Cited by 88
Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease
Dorfman, V. B., Pasquini, L. A., Riudavets, M. A., López‐Costa, J. J., Villegas, A., Troncoso, J. C., Lopera, F. J., Castaño, E. M., & Morelli, L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.09.016 · Cited by 94
Muñoz, F. J., & Inestrosa, N. C. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00468-8 · Cited by 91
Fawzi, N. L., Okabe, Y., Yap, E.-H., & Head-Gordon, T. L. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.10.011 · Cited by 90
Cerebrospinal Fluid Aβ to Tau Ratio and Postoperative Cognitive Change
Xie, Z., McAuliffe, S., Swain, C. A., Ward, S. A. P., Crosby, C. A., Zheng, H., Sherman, J. C., Dong, Y., Zhang, Y., Sunder, N., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318298b077 · Cited by 92
Correlation Between Aβx-40–, Aβx-42–, and Aβx-43–Containing Amyloid Plaques and Cognitive Decline
Parvathy, S., Davies, P., Haroutunian, V. H., Purohit, D. P., Davis, K. L., Mohs, R. C., Park, H., Moran, T. M., Chan, J. Y., & Buxbaum, J. D. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.2025 · Cited by 90
Alzheimer’s disease – the journey of a healthy brain into organ failure
Golde, T. E. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00523-1 · Cited by 98
Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility
Theuns, J. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.16.2383 · Cited by 89
Metadata
- Authors
- Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G.
- Affiliations
- Case Western Reserve University (US)
- Takeda (Japan) (JP)
- Corresponding author
- Younkin, Steven G.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1995-03
- Volume
- 270
- Issue
- 13
- Pages
- 7013-7016
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1618236677
- Cited by
- 676
- References
- 20
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 19 · 2023: 21 · 2022: 23 · 2021: 33 · 2020: 33 · 2019: 22 · 2018: 18 · 2017: 22 · 2016: 27 · 2015: 20 · 2014: 22 · 2013: 24 · 2012: 24
- FWCI
- 17.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag012685-04)
- National Institute on Aging (AG06656, R01AG006656, AG12685)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, Alzheimer's disease, amyloid-beta 42, Aβ40, cerebral amyloid angiopathy, amyloid plaques, cerebral cortex, vascular wall, amyloid deposition, cerebrospinal fluid
- MeSH terms
- Alzheimer Disease, Cerebral Cortex, Chromatography, Gel, Enzyme-Linked Immunosorbent Assay, Humans, Immunohistochemistry, Reference Values, Temporal Lobe, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-27, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
